The company focuses on a clinical-stage biopharmaceutical pipeline focused on gastrointestinal cancers, rare diseases and other unmet medical needs, with programs including eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, MTX240 for gastrointestinal stromal tumors, and tolimidone for type 1 diabetes. The company also offers drug delivery platforms including Q-Sphera, MidaSolve, and MidaCore nanoparticle technologies.
Cyborg Score Rationale
Small revenue, heavy losses, and highly negative returns on equity and assets characterize the company. 2026 revenue is projected at $1,051,351 while the company is pre-commercial on its pipeline, though recent clinical progress and partnership announcements have generated investor interest.
Top Insights
Launched global Early Access program with Tanner Pharma in March 2026 for eRapa to treat Familial Adenomatous Polyposis, enabling clinicians to prescribe investigational oral rapamycin capsules outside clinical trials while collecting Real World Data.
Licensed MTX240 from Otsuka in February 2026, a Phase 1-ready molecular glue for gastrointestinal stromal tumors with orphan drug eligibility and a Phase 1b/2a trial planned by year-end.
Maintains collaboration agreements with Janssen and Melior.
Completed an ADR ratio change from 1 ADR = 100,000 shares to 1 ADR = 500,000 shares effective April 6, 2026 to support NASDAQ compliance.
Named Competitors
Vertex — Rare disease and genetic medicine developer
Argenx — Immunology and rare disease biopharmaceutical
Grifols — Plasma-derived medicines and diagnostics
Recent Developments
(May 2026) Proposed major share capital reorganization ahead of June AGM
(April 2026) Announced manufacturing partnership with Syngene for MTX240 GMP clinical trial supplies
(March 2026) Launched global Early Access program for eRapa with Tanner Pharma Group
(February 2026) Licensed MTX240 from Otsuka for gastrointestinal stromal tumors
(January 2026) Appointed Fiona Sharp as Chief Financial Officer
Open the full interactive Biodexa Pharmaceuticals Plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.